MEMPHASYS LIMITED. — Capital/Financing Update 2014

Jan 19, 2014

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 24] intentionally omitted <==

FOR IMMEDIATE RELEASE

NuSep Working Capital Advance

Sydney, Australia 20[th] January 2014 – NuSep Holdings Ltd (ASX:NSP) wishes to advise the market that it has arranged a $250K working capital advance.

This fully drawn working capital facility has been provided on the following terms. The interest rate on this facility is 15% pa which, subject to shareholder approval, will be paid in NuSep fully paid ordinary shares. The conversion to shares is based on the 5 day VWAP of NSP’s trading days immediately prior to the loan date. The working capital facility is due for repayment on 24[th] April 2014. The loan facility is secured over the assets of the Company and has been provided by Mr Andrew Goodall. Mr Goodall is a non-executive Director of NuSep.

As part of this facility, the Company has agreed subject to shareholder approval, to issue Mr Goodall and/ or nominee with 375,000 unlisted NSP share options with an exercise price of 11.2 cents ($0.112) which is 150% of the 5 day VWAP of NSP’s trading days prior to the loan date. These share options expire on 20[th ] January 2016.

- END-

For more information please contact:

Contact: Prakash Patel Managing Director +61 2 8415 7300 prakash.patel@nusep.com

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques based on its PrIME[1] technology. The PrIME technology has produced a number of world firsts including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

1 PrIME stands for Pr eparative I solation by M embrane E lectrophoresis NuSep Holdings Ltd Postal Address Contact Details Email info@nusep.com 30 Richmond Rd P.O. Box 2202 Telephone +61 2 8415 7300 Web www.nusep.com Homebush NSW 2140 Homebush West NSW 2140 Facsimile +61 2 8415 7399 ABN 33 120 047 556

– 2 –

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

• Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

• Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

• Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin .

For more information about NuSep please visit the company’s website www.NuSep.com

About PrIME Biologics Pte Ltd

PrIME Biologics is a Singapore based biotech company that has developed a disposable therapeutic plasma manufacturing process based on NuSep’s PrIME Technology. PrIME Biologics process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause ‘Mad Cow Disease’. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PrIME process will be the Currently Unprocessable Plasma which represents approximately 50% of all the plasma collected in many Asian countries.